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Introduction
Clinical genetics has established itself as a medical practice in which patients
are addressed primarily as individuals who have to make informed choices
(Bosk ; Steendam ). Historically, centres for clinical genetics in the
Netherlands have a privileged position in offering genetic counselling and ge-
netic testing, and function as “gatekeepers” for those seeking genetic consul-
tation and diagnosis (Nelis ). In these centres, genetic diagnosis is em-
bedded in a practice of counselling in which facts deemed relevant are sepa-
rated out as “information” that is handed out to clients along with a few
courses of action formulated as possible alternatives and between which
clients are requested to choose. The establishment of clinical genetics thus
created a particular space for individual decision making in which, from the
s onwards, new options for genetic testing on the basis of -diagnosis
have been introduced and evaluated primarily as bringing along new oppor-
tunities of choice (Bourret et al. ).
In today’s health care, this particular configuration – that of the individual
patient called upon “to decide” – is held in high esteem. A good doctor leaves
patients room for choice. But how can we understand the issue of individual
choice when we simultaneously consider the rapidly developing practices of
medical genetics from a perspective of co-production of technology and soci-
ety? From this perspective, we are interested in the question of how techno-
logical objects and individual subjects – nonhuman and human agents – mu-
tually shape one another in an emerging web of socio-technical relations
(Berg and Mol ). Looking at recent developments in medical genetics in
this way, we can make two observations.We see the emergence of increasingly
complex networks, involving a growing interdependency between many dif-
ferent actors: technologies of screening, registries, medical specialists, pa-
tients, clinical genetics centres, and individuals at risk. At the same time, we
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see how in this network a particular model of human agency is endorsed, ac-
cording to which it is the individual patient or person at risk who has to de-
cide.
How should one weigh these observations? Should we interpret them as
revealing a tension or even contrast between “structure” – embodied in net-
works and interdependencies – and “action” – embodied in individual free-
dom of choice? Or should we understand the model of individual decision
making as a particular outcome of a process of co-production of technology
and society? Framed in this way, our observations invite us to go beyond “an
oscillation in social analysis between action as determining and action as de-
termined” (Gomart and Hennion ). That is, we are invited to shift the
analysis to the collective production of human agency, to the creation of par-
ticular subject positions as an effect of emergent socio-technical networks.
In this chapter, we attempt to take up this invitation in an analysis of how
subjects and responsibilities are constituted in new emerging practices of
screening in the field of cancer genetics. We focus our study on the way in
which in the Netherlands a screening practice has emerged for familial ade-
nomatous polyposis (), a specific hereditary predisposition for colon
cancer. First, we shall show how in the s a regular screening practice was
created which involved both patients and “individuals at risk”. Then we de-
scribe how this screening practice was extended with new elements, with the
development and introduction of -diagnostic tests, involving new choic-
es and responsibilities. Thus, we shall cover the way in which responsibilities
were distributed and human agency was shaped in these various contexts. In
conclusion, we shall discuss our findings in the context of current debates
about patient autonomy and freedom of choice in today’s health care and the
emerging new genetics.
 in the early s: the emergence of a screening practice
In  a collection of three articles and a commentary appeared in an issue of
the Dutch Journal of Medicine, which focussed on the clinical experiences in-
volving a rare, dominantly hereditary disease, called polyposis coli or familial
adenomatous polyposis (). In each of the three articles, an elaborate de-
scription was given of the history of the disease in a particular family. One of
the articles opened with the story of a -year-old woman who consulted the
clinic because a -year-old cousin of hers had been recently identified as an
 patient after the diagnosis of colon cancer (De Ruiter and Den Hartog
Jager ). The mother of the woman had died of colon cancer when she was
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, a few years after the colon had been partially removed because of a malig-
nant polyposis. The authors of the article observed with regret that clinical
examinations of relatives had not been undertaken at the time, although it
was known that a grandmother and a great-grandfather had also died from
“cancer of the colon”. The woman who was consulting the clinic had no
symptoms, but inspection of the colon revealed many polyps resulting in a
subsequent diagnosis of  and in the decision to completely remove the
colon. The article then continued with the case of a younger sister of the
woman, who similarly displayed no symptoms, but who also had her colon
removed after investigation had indicated polyposis. Other brothers and sis-
ters examined only revealed a few polyps in the colon. In these cases, as the
authors point out, the examination had to be repeated every year. In conclu-
sion, the article reports the results of examinations that had been carried out
on  people, spanning two generations of the family. Polyposis was found in
 cases, and colon cancer had already developed in  of them. Four people re-
fused the invitation to undergo examination.
The collective publication of the three articles and the accounts given by
the authors of the diagnosis, treatment and screening in families where  is
found may be seen as an event which marks the emergence of a specific clini-
cal practice, i.e., a practice in which the professional responsibility of the
medical specialist – an internist or gastro-enterologist – cannot be restricted
to the individual patient, but should also extend to the health and survival of
the patient’s relatives (see figure  below). When a patient finally consults the
clinic with specific symptoms and the diagnosis of  is made, in most cases
a fatal colon cancer will have already appeared. Thus, as the authors of the ar-
ticles point out, it is of vital importance to trace the families in which  is
found and to screen the members of these families every two or three years,
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Figure : Emergent cancer genetic practice in the field of polyposis (late s)
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beginning from about the age of ten. As soon as more than one hundred
polyps are found in the colon, the diagnosis of  should be made, and it is
only by complete removing the colon that the development of cancer can be
prevented. Even then, regular screening remains necessary. If, on the other
hand, family members are still free of symptoms between the ages of forty
and fifty, the appearance of polyposis can be reasonably counted out, and
screening may be terminated.
The conclusions and recommendations of the authors were clearly intend-
ed to promote a practice that, at the beginning of the s, was still in its in-
fancy. At that time, it was already considered against due practice to refrain
from an extensive family anamnesis when the diagnosis of  had been
made.However, in the preceding period, this kind of family anamnesis was by
no means the rule, which is explained, in one of the articles, by a general lack
of knowledge of the serious consequences of the disease. Even when an exten-
sive mapping of the family history of the patient followed the diagnosis of
, it was often considered to be an impossible task for the individual spe-
cialist to actively approach all the family members involved. And, as far as
family members were actually approached, the specialist could not always be
sure that they would return regularly for periodic screening. Thus, in a com-
mentary on the three articles mentioned above,published in the same issue of
the Dutch Journal of Medicine, it was observed that:
Detective-like genealogical investigations, the psychological burden ex-
perienced by people who feel completely healthy and yet face the
prospect of invasive examinations of the colon, and the not always inter-
esting task to screen a fairly large number of people who have no symp-
toms, require a great and unremitting enthusiasm and dedication of
those who undertake to follow a family with a history of polyposis. (Van
Slooten )
Hence, the author of the commentary argued for the establishment of a cen-
tralised national registry, which could send out a reminder to medical spe-
cialists each time a person at risk had to be called in for screening. The results
of the screening were to be returned to the registry. If no results followed, the
organisation could take further action in order to safeguard the care for those
at risk and to obtain certainty about their conditions. With his plea, the au-
thor actually repeated a message that he had already voiced in the same jour-
nal no less than  years earlier. This time, however, the argument would find
an audience.
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Late s: The establishment of a national registry
At the end of the s, a patient consulting a clinic with symptoms of 
would encounter a practice that was indeed different from what we have seen
earlier. The medical specialist in attendance now not only had to inform the
patient about the hereditary nature of the disease and the importance of
screening family members, but also could refer the patient to the national
Foundation for the Detection of Hereditary Tumours. In , this foundation
was established by a number of specialists involved in the treatment of pa-
tients and their families suffering from hereditary tumours (one of the
founders was the author of the commentary quoted above). In , the
Foundation started a national registry of families with a history of , thus
aiming to promote screening in high-risk families, to guarantee the continu-
ity of screening, to collect data for scientific purposes, and to offer advice
about the diagnosis, treatment, methods of screening, and genetic services
for counselling (Vasen et al. ).
The result of this development was a more extended practice of diagnosis,
treatment and screening of , in which every patient is reported by medical
specialists to the Foundation for the Detection of Hereditary Tumours (see
figure  below). A social worker at the Foundation then approaches the pa-
tient and with his or her help draws up a family tree which makes it possible to
trace the history of the disease and to identify members of the family who are
at risk. The patient is asked to inform relatives at risk and to urge them to have
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Figure : Establishment of a national registry in the field of polyposis (late s)
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themselves screened. If they agree, family members are approached by the
Foundation with a request for registration. In this way, nearly all  families
in the Netherlands have been registered, amounting to a few hundred (Annu-
al report ). Personal and medical information is collected from those
who have registered, and through a system of reminders, specialists are noti-
fied when individuals should be called in for screening. If no screening results
are reported, and upon inquiry it appears that someone did not turn up for
screening, the registry will send out a request to the family doctor to take ac-
tion and to remind this person that screening is of vital importance.
While the care of individuals with a risk of  initially strongly depended
on the enthusiasm and efforts of individual specialists and on the awareness
of those at risk, it is now the Foundation for the Detection of Hereditary Tu-
mours which has assumed the responsibility for the organisation and conti-
nuity of screening and which “will put all efforts into encouraging (regis-
tered) individuals to comply (with regular screening)” (Annual report ,
). Indeed, as those working at the Foundation point out, in order to motivate
family members to participate in a screening program,good information and
a personal approach including home visits are necessary (interview data, see
footnote ). Moreover, through the establishment of a national registry, in-
formation is collected which not only facilitates the organisation of a screen-
ing program, but which also creates possibilities for a systematic follow-up
and an evaluation of its results. For that purpose, two national working
groups on , involving various forms of expertise, collaborate with the
Foundation in the organisation of studies and the establishment of guide-
lines (Vasen et al. ). Thus, through the efforts of the Foundation, local
practices of early detection and prevention have become part of a larger net-
work in which these practices are organised and regulated on a national scale.
Early s: The advent of DNA-diagnosis
In the early s, a patient who consulted the clinic with  symptoms
would again encounter a practice that had been extended with new elements
– new technologies, rules and organisations (Vasen and Müller ). In ,
molecular biologists succeeded in relating the occurrence of  to muta-
tions in a particular gene, the so-called  (adenomatous polyposis coli)
gene. This finding made available the possibility of presymptomatic -di-
agnosis whereby members of an  family could be informed about their in-
dividual riskstatus on the basis of mutation analysis, that is, whether they will
get the disease or not. However, in the Netherlands, -diagnosis is made
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available only through a network of regional clinical genetics centres. Thus,
with the advent of the -diagnosis of , molecular biology laboratories
and clinical genetic centres became part of the network in which the practice
of diagnosis, treatment, and screening of  took shape (see figure  below).
A new patient will now not only be reported by a medical specialist to the
Foundation for the Detection of Hereditary Tumours, but will also be re-
ferred to a clinical genetics centre for mutation analysis. Again, a clinical ge-
netic centre counsellor will draw up a family pedigree in order to identify rel-
atives who may be at risk of developing the disease. Family members of the
family then have the opportunity (after being been informed by the patient)
to be referred to a clinical genetics centre, which may offer them presympto-
matic -diagnosis as soon as a mutation is found. Those who accept the
offer and are diagnosed as carriers know for certain that they will develop 
and that regular screening is the only way to escape from an early and deadly
cancer. Of those diagnosed as carriers, most if not all will have themselves
registered in the national registry at the Foundation for the Detection of
Hereditary Tumours. Those who are diagnosed as non-carriers, however, are
excluded from risk and thus may abstain from participating in a burdensome
and protracted screening program. In other words, -diagnosis made it
possible to divide a known population at risk of contracting  into a carrier
group which can be followed with traditional clinical screening methods,and
a non-carrier group which may be excluded from risk and relieved of partici-
pation in a screening program. For those who appear to be carriers, -di-
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Figure : Introduction of DNA-diagnosis in the field of polyposis (s)
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agnosis may have additional value in decisions about prophylactic interven-
tions, and is available in the form of prenatal diagnosis. Thus, options for
-diagnosis were readily incorporated in clinical practice as a diagnostic
tool which contributes to more efficient and improved forms of preventive
care.
A network of co-existent regimes
In the previous sections we described the emergence of a national screening
program in the field of cancer genetics as a process of co-evolution, showing
changing configurations of artifacts, practices, professions, users and institu-
tions in which a particular case of “new genetics” has been gradually taking
shape. We have described these changing configurations as an extending net-
work, that involved new actors – family members potentially at risk, social
workers, a national registry, clinical geneticists – and established new align-
ments between these actors. In this network, the provision of information to
family members about the hereditary nature of the disease, the establishment
of family trees, the collection of medical data, the offer of -diagnosis and
clinical screening became standard elements of the responsibilities of the
medical specialist, social worker, or clinical geneticist. The data collected
through this network and these efforts, by the Foundation for the Detection
of Hereditary Tumours, facilitated not only the organisation of a national
screening program, but also the systematic monitoring of its effects and the
development of guidelines to be observed in practices of diagnosis and
screening. Thus, the extending -network embodied a long-envisaged task
to improve the management of polyposis as a hereditary disease.
Our previous account of the emergence of an -network not only de-
scribes the mutual shaping or co-evolution in which  was transformed
from a “fatal disease of the colon” into a “hereditary disorder with preventa-
ble consequences”. It also shows how this process of co-evolution crystallised
into a specific pattern of roles and responsibilities that the actors involved
found difficult to deny. In the s, actions and interactions in the evolving
-network both shaped and were shaped by what we might call a new
regime of prevention. In the early s, as the publications in the Dutch Jour-
nal of Medicine show, medical specialists were already expected to inform 
patients about the hereditary nature of the disease and the consequent impli-
cations for family members. The responsibility of the physician no longer
stopped with the treatment of a patient, but also extended to the patient’s
family. Relatives had to be informed about potential risks and if necessary, ac-
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cording to the ruling standards of the time, considered for regular screening.
With the establishment of a national registry, the responsibility of individual
specialists to offer information and care to the family of patients became in-
stitutionalised on a more collective level in the working practices, database
and protocols of the Foundation for the Detection of Hereditary Tumours. In
other words, through the efforts of the Foundation, practices of early detec-
tion and prevention no longer depended primarily on local initiatives, but
had become part of a larger cancer genetic regime of prevention.
When, in the early s, researchers in Leiden found genetic markers on
both sides of the so-called  gene, it became possible to identify gene carri-
ers in families at risk through linkage studies (no direct mutation analysis was
possible yet). However, the provision of a -test did not come within the
province of the gastro-enterologist or the Foundation for the Detection of
Hereditary Tumours. It was the Leiden Centre for Clinical Genetics that or-
ganised and facilitated the introduction of -diagnosis in  families.As
we have already noted in the introduction, centres for clinical genetics in the
Netherlands have a privileged position in offering genetic counselling and ge-
netic testing, and in these centres, genetic diagnosis is offered through a prac-
tice of counselling in which the autonomous decision making of patients and
individuals at risk is the guiding principle. When providing information,
counsellors consider it as their task to be neutral and non-directive. The re-
sponsibility for decisions and actions to be taken is delegated primarily to the
individual asking for information and advice. In the practice of genetic coun-
selling, the principle of informed decision making is also upheld by the rela-
tively long time available for each consult, the obligatory time-frames be-
tween consults when clients have to make important decisions,and the exten-
sive documentation of consultations that counselors provide to their clients.
In other words, when -diagnosis became available for those at risk of
contracting , it was embedded in a practice of clinical genetics that al-
ready constituted a regime of its own. In this regime, self-determination was
the guiding principle that defined the roles and responsibilities of the actors
involved (Nelis  and ). In this context, it is interesting to see how
medical specialists, in the early s, considered the prospects of -diag-
nosis in the field of cancer genetics.They referred,first of all, to the promise of
improved forms of preventive care, but also pointed out that genetic coun-
selling would deserve particular attention because those at risk of contracting
(rare) hereditary tumours would have to face more complex choices (Vasen
and Müller ). This comment, no doubt, strongly reflected the history and
position of clinical genetics as a practice in which -diagnosis was made
available to patients and individuals at risk primarily as an opportunity of
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(informed) choice. In other words, in our account of the emerging -net-
work, the introduction of options for -diagnosis not only involved the
extension of this network with a few new elements, but also created a situa-
tion of co-existence in this network of two different regimes. Indeed, from the
s onwards,  patients and individuals at risk found themselves being
addressed in different ways: as subjects who need preventive care and as sub-
jects who have to deal with (new) opportunities of choice.
Ethical norms: External standards or constitutive elements? 
From the perspective of more traditional medical ethics, one might argue
that our description of a regime of prevention reveals a paternalistic ap-
proach towards the choices of individuals at risk, while in a regime of self-de-
termination, professionals rightfully comply to the principles of autonomy
and informed consent as defined both by ethical and legal standards. The
medical ethics perspective differs in a number of ways from the perspective
that we try to develop in this chapter. Most importantly, within the tradition
of medical ethics, norms such as patient’s rights to free choice and au-
tonomous decision making are defined as external to medical practices, that
is, as universal standards which are supposed to guide and direct the daily ac-
tivities of medical professionals. In contrast to this view,we want to argue that
medical standards, rather than being external and given, are constitutive ele-
ments being co-produced within medical practices.
As empirically oriented philosophers and -scholars have argued, pa-
tient autonomy, conceived as a universal normative ideal or ethical standard,
may be difficult to localise in current everyday practices of medical care. For
example, in an empirical study of decision making practices in a hospital set-
ting, Schermer concludes that decision making in daily care-settings is an on-
going and diffuse process. Decisions are rarely made at one time, in one loca-
tion or by one person, let alone by “the” individual patient. On the contrary,
“there were many moments, with many smaller and bigger decisions cluster-
ing together” that jointly produced a particular trajectory or action (Scher-
mer , ). What we see then is a variety of incidental decisions which are
not so much geared towards the question “what does this patient want?” but
to the question “what is best for this patient?”. According to Schemer, that
does not necessarily imply that there is a lack of respect for the autonomy of
patients in hospital practices. Rather, one could say there are different mean-
ings of autonomy that shape the relationship between the patient and the
medical professionals. Autonomy has “different faces”.
 Dirk Stemerding and Annemiek Nelis
Inside the Politics of Technolo  24-06-2005  10:58  Pagina 118
Schermer’s argument may be read as a critical evaluation of everyday med-
ical practices which takes the normative ideal of patient autonomy as a start-
ing-point. However, we may also understand her observations from a differ-
ent point of view in which norms are not taken as ideals coming prior to the
reality of everyday practices, but as being co-produced in the activities, rules,
routines and procedures in which such practices take shape. From this per-
spective, Schermer’s argument also applies to our description of different
regimes in the -network, showing how particular subject positions – be it
the autonomous patient or the patient needing good care – emerge in various
medical practices.
Well-being versus autonomy
Schermer’s description of the practices and routines of hospital care obvious-
ly has much in common with our previous account of the ways in which pa-
tients and individuals at risk move through a -network constituting what
we have called a regime of prevention. In accordance with Schermer’s obser-
vation that “it seemed as if considerations concerning a patient’s well-being
were far more important than considerations concerning patient autonomy”
(), we find in this regime of prevention a strong focus on the well-being of
individuals and families at risk. Indeed, the primary aim of the Foundation
for the Detection of Hereditary Tumours is to guarantee optimal care, and so
it does everything in its power to encourage individuals to co-operate. In this
context, the notion of choice only appears as a valuable opportunity or as a
boundary that one should respect. As one of the social workers of the Foun-
dation explains:
Because of privacy regulations we are not allowed to approach members
of the family without their personal consent. Thus, patients are invited
by the Foundation to inform relatives at risk. Personal contact with pa-
tients at home makes it easier to persuade them that it is necessary to in-
form other members of the family and also to convince them of the ben-
efit of screening. Sometimes, when patients are reluctant, the family doc-
tor is called in. If members of the family don’t want to be informed, then
there is nothing more to be done.
Although professionals within the regime of prevention thus occasionally re-
fer to the notion of individual choice as a valuable and indispensable oppor-
tunity, the organisation of screening and medical decision making in the
-network is governed by judgements, routines and standards in which the
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medical well-being of patients is clearly assigned priority over other consid-
erations.
This is not to say, however, that individual autonomy only exists as a nor-
mative ideal to be confronted with the reality of day-to-day medical practices.
Individual autonomy as a standard may also become part of everyday reality,
as in the regime of self-determination constituted by the history and practice
of clinical genetics. In this practice too, the roles and responsibilities that are
ascribed to patients and individuals at risk are shaped by routines and stan-
dards indicating the best course of action in the process of medical decision
making. Thus, when an individual at risk of contracting polyposis consults a
genetic centre for -diagnosis, the counsellor will meet this person on the
basis of a specific protocol. In the words of a counsellor:
According to the protocol, applicants for a pre-symptomatic test first see
a clinical geneticist and a psychologist. The clinical geneticist discusses
the history of the disease and the personal reasons for a pre-sympto-
matic test. Then there is a meeting with one of the psychologists who dis-
cusses the implications of pre-symptomatic testing. This is followed by a
four-week period to think the matter over, after which the applicant re-
turns for a final discussion and decision about the test.
Although the subject positions created for  patients and individuals at
risk are clearly different in the two regimes we have described, we may con-
clude that in both regimes these positions can be understood as the emergent
result of standards, routines and protocols shaping, and being shaped by, the
everyday practices of medical decision making.
Standard patients
In her study of decision making practices, Schermer also observes that when
the preferences of patients are taken into account, medical professionals of-
ten refer to what they presume patients in general deem as important, that is,
to the image of the average or “standard” patient. This observation likewise
applies to the efforts of those involved in the -network. As medical spe-
cialists have been increasingly convinced of the necessity to regularly screen
members of families at risk of contracting , they have created new courses
of action for patients and their relatives, and thus also new opportunities of
choice. However, in adhering to the rules and standards of a regime of pre-
vention, medical specialists are not seeking more room for choice, but are
seeking opportunities to improve care. The course of action indicated is de-
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fined by the image of a standard patient who wants to know about his or her
risks. Indeed, diagnosis and treatment of and screening for  are seen as
matters of life (longer) or death (early),and decisions about preventive meas-
ures are primarily perceived as medical issues from this perspective (Menko
et al. a, b). Such decisions thus will be generally discussed and pre-
sented in terms of necessary interventions about which there is little scope for
choice. Reflecting on his discussions with  patients in the consultation
room, a gastroenterologist comments:
The days that the doctor knew best are long gone. Choices and risks re-
lated to the timing and nature of surgical interventions all have to be
clearly discussed with the patient. There are a lot of things that have to be
considered, including of course the wishes of the patient. … Of course,
when a colon is full of polyps, it is our task to deliver the message, to say
what must be done, and that is, you know, what always will be done.
Of course, not everybody conforms to the image of the standard patient.
Sometimes a patient is not prepared to inform other members of the family.
And not everyone at risk really wants to be informed. In living their lives and
their disease, people thus may choose to follow different trajectories. Howev-
er, with the emergence of a practice of clinical screening and its development
into a cancer genetic regime, some trajectories have been made more com-
fortable and predictable than others. In the early s, it required a great deal
of effort for a medical specialist to maintain a program of screening that
would allow every individual at risk to be informed and undergo regular ex-
amination. Today, a national registry, social workers who visit patients at
home, information leaflets, a system of reminders, working groups, survival
rates, guidelines form the constitutive elements of a regime of prevention, of-
fering patients and relatives at risk a course of action that is difficult for them
to refuse.
In the regime of self-determination, we indeed find another image of the
standard patient as someone who has a great stake in self-determination and
non-interference. Thus, in the day-to-day practice of clinical genetics, every-
thing is done to uphold non-directiveness and informed freedom of choice.
But, as we have noted above, the presumptions made about the values and
preferences of the standard patient need not always match the wishes or views
of the individuals involved. For example, in moving through the -net-
work, many patients or individuals at risk experience the genetic centre as
“just a stop on their way to the surgeon”(Dudok de Wit , ). They expe-
rience their choice as a purely medical decision and sometimes feel annoyed
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by appointments with a clinical geneticist or psychologist taking time to ex-
plain the implications of predictive testing. As Schermer already noted, au-
tonomy may have many different faces indeed!
Conclusion: Where do the choices lie?
In our description of the emergent -network in terms of two co-existing
regimes, we have focussed on a particular contrast in the ways in which roles
and responsibilities are assigned to patients or individuals at risk. In a regime
of prevention, individuals are presumed to act as obedient clients with an in-
terest in strategies to prevent future disease, whereas in a regime of self-deter-
mination, their role is one of autonomous decision makers, capable of articu-
lating their own will and making use of their right to freedom of choice. In
discussing these different subject positions we did not start from a particular
notion of the human subject. We have described these positions as constitut-
ed in particular practices, that is, as being shaped by a variety of standards,
routines, guidelines, forms and services. Thus, in our account, individual au-
tonomy is not taken as a normative and political ideal to be contrasted with
the realities of everyday practice. We see the act of self-determination as one
of the possible, collective outcomes or effects of the association of a socio-
technical network. In the words of Annemarie Mol, we are talking about on-
tological politics, in which “the crucial moments are not those where ‘pa-
tients’ act as agents, but rather those where they are defined, measured, ob-
served, listened to, or otherwise enacted”(Mol , ).
Our perspective marks a significant distance from a normative position
that starts from a conception of the human subject as a rational, liable and ac-
countable being, thus presupposing freedom of choice is a fundamental con-
dition of existence. From this position, autonomous decision making serves
as a universal normative ideal, and the question as to whether individuals
have been able to realise their autonomy is considered the major issue in any
normative discussion. In our analysis, however, we have tried to move away
from dualistic accounts in which autonomy is opposed to paternalism, non-
directivity opposed to directivity, and free choice opposed to forms of pres-
sure. We are interested in the questions of where, when and how choices and
autonomy appear as part of a story in which the “good” may have many dif-
ferent faces and need not be necessarily related to autonomous decision mak-
ing (Mol ). Thus, in the consultation room of the gastro-enterologist,
choices may appear as a valuable option when discussing the operation date
with a young  patient who first wants to finish school and find a job.But in
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another situation – when a colon is full of polyps – the doctor, in the words of
a gastro-enterologist, simply will have to specify what must be done. In the
genetic centre, choices indeed are the trademark of a clinical geneticist. Nev-
ertheless, when the consequences are very straightforward, as with , and
somebody does not want to talk and just goes for a blood test,one need not, in
the words of a counsellor, always adopt a “holier-than-thou” attitude (inter-
view data, see footnote ).
Seen from this perspective, the question is not how to evaluate the different
practices and regimes in an -network in terms of freedom of choice as a
universal normative point of view. Rather, we suggest that in order to under-
stand and evaluate the normative implications of medical practices, we need
first of all to understand what “choice” requires and implies in various con-
texts and thus to study the various ways in which choice may, or may not, be-
come an issue in a variety of local and specific situations.
Notes
 We would like to thank Brenda Diergaarde and Annemarie Mol for their contri-
bution to the research that was performed in order to write this article.
 In practice, however, the option of prenatal diagnosis appears to be rarely used
(Whitelaw et al. ).
 According to Rip and Kemp (, ) a technological regime may be defined as
“the rule-set or grammar embedded in a complex of engineering practices, pro-
duction process technologies, product characteristics, skills and procedures, ways
of handling relevant artifacts and persons, ways of defining problems – all of
them embedded in institutions and infrastructure”.
 This does not imply that other medical practices are naturally directive.What we
argue here is the particular emphasis on patient autonomy in the definition and
practice of clinical genetics.Whether a non-directive approach is actually possi-
ble is another matter. For a critical review of non-directiveness and neutrality, see
Van Zuuren (, ), Steendam (), Michie et al. ().
 Paternalism we take here as an act that is performed independent of the wishes of
another but with the intention to act to the benefit of that other (Ten Have et al.
).
 See, for example, Berg and Mol (), Mesman (), Schermer (), The
().
 For example, Schermer () argues that as patients often leave the decision
making in the hands of what they consider competent professionals, these profes-
sionals will experience a moral duty not to harm the trust placed in them.
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 The quotations in this section are taken from interviews with a social worker from
the Foundation for the Detection of Hereditary Tumours, a clinical geneticist
from the Centre of Clinical Genetics in Leiden, and a gastroenterologist from the
University Hospital in Nijmegen.
 Also, the opposite experience of patients has been noted. For example, in his study
of a practice of genetic counselling, Charles Bosk observes that when parents had
to make a choice, they often felt left alone by the genetic counselor who in their
eyes refrained from taking the responsibility of making the decision with them
(Bosk ).
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